Actively Recruiting
A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation
Led by Jemincare · Updated on 2025-07-01
72
Participants Needed
1
Research Sites
129 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a phase 1b, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and efficacy of JMKX001899 in combination with IN10018 or in combination with chemotherapy or in combination with IN10018 and chemotherapy in subjects with locally advanced or metastatic NSCLC with KRAS G12C mutation.
CONDITIONS
Official Title
A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically or cytologically confirmed Stage IIIB, IIIC, or IV NSCLC not suitable for surgery or definitive chemoradiation
- Presence of KRAS G12C mutation and negative for other driver genes with approved targeted therapies
- Measurable disease by RECIST 1.1 criteria
- ECOG performance status of 0 or 1
- Adequate organ function
You will not qualify if you...
- Carcinomatous meningitis or spinal cord compression, or uncontrolled CNS or leptomeningeal metastases
- Prior chemotherapy, radiotherapy, immunotherapy, or investigational treatment within 4 weeks (6 weeks for nitrosoureas or mitomycin C; 2 weeks for small molecule targeted therapies or traditional anticancer medicine)
- History of other malignancy within past 3 years except curatively treated cancers
- Gastrointestinal disease preventing oral medication intake or affecting drug absorption
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China, 510080
Actively Recruiting
Research Team
J
Jieting Zhao
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here